AstraZeneca Trips On Unexpected Failure In Breast Cancer

AstraZeneca and Daiichi Sankyo's Enhertu showed positive results in a phase 3 trial for HER2-mutant non-small cell lung cancer, delaying disease progression compared to standard treatment. The DESTINY-Lung04 study involved 454 patients and met its primary endpoint of progression-free survival. Full data will be presented at a future medical meeting. The companies plan to share the results with regulators for potential label expansion. According to the companies, this success could support earlie

AstraZeneca (AZN) reported that its SERENA-4 Phase III trial for Etcamah did not meet its primary endpoint but showed clinical benefits in a specific breast cancer subgroup. The company offers a 2.05% dividend yield with a 47% payout ratio, and its stock is considered 12.0% undervalued based on a GF Value™ of $182.10. AstraZeneca has a GF Score™ of 77, indicating strong fundamentals. Institutional interest is mixed, with 8 gurus adding and 7 trimming positions. Insider sales totaled $2.2 million

AstraZeneca announced that its drug Etcamah, a selective estrogen receptor degrader (SERD), failed to meet the primary endpoint in a Phase III trial for first-line breast cancer treatment. The trial aimed to evaluate the drug's efficacy in combination with other therapies. According to the company, the results were not statistically significant, leading to the trial's discontinuation. This setback may impact AstraZeneca's oncology pipeline and investor expectations.

AstraZeneca announced that its late-stage trial for the breast cancer drug Etcamah did not meet its primary goal. The company's shares have declined 0.43% in the last five days and 3.61% since the start of the year.

AstraZeneca's breast cancer drug, camizestrant (Etcamah), failed to meet the main trial goal of improving progression-free survival when combined with Pfizer's Ibrance, the company reported. U.S.-listed shares fell 3% in aftermarket trading. The trial involved 1,371 patients with advanced breast cancer. Analysts view this as a manageable setback, with peak sales potential estimated at over $5 billion by Jefferies.

AstraZeneca's breast cancer drug, Etcamah, failed to meet the primary endpoint in a late-stage trial, causing a 3% drop in its U.S.-listed shares. The trial tested the drug in combination with palbociclib for advanced breast cancer. AstraZeneca plans to share full trial data later. The FDA recently granted accelerated approval for Etcamah with certain targeted cancer medicines.